ABSCF Stock Chart & Stats
$1.12
$0.00(0.00%)
At close: 4:00 PM EDT
$1.12
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$1.12 - $1.45
Previous CloseN/A
Volume200.00
Average Volume (3M)0.00
Market Cap
$63.26M
Enterprise Value$106.38
Total Cash (Recent Filing)$10.18M
Total Debt (Recent Filing)$4.24M
Price to Earnings (P/E)―
Beta0.06
Next Earnings
Oct 09, 2026EPS Estimate
-0.08Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.04
Shares Outstanding96,530,785
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.73
Price to Book (P/B)-5.48
Price to Sales (P/S)80.33
P/FCF Ratio-20.63
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.17
Revenue Forecast (FY)$1.38M
Bulls Say, Bears Say
Bulls Say
Recent Revenue GrowthImproving revenue demonstrates that AB Science is generating greater commercial or collaboration-related inflows despite its small scale. Continued top-line progress could provide a stronger base for development funding and improve operating leverage if the company advances toward product authorization.
Sharp Debt ReductionThe substantial reduction in debt lowers interest and refinancing pressure and represents a meaningful improvement in financial flexibility. Although the balance sheet remains fragile, a much smaller debt burden can help preserve capital for clinical development and reduce obligations during periods of cash burn.
Proprietary Drug Development PlatformA proprietary small-molecule platform centered on masitinib gives AB Science several potential development paths across oncology and immune-related diseases. Progress in multiple indications can diversify clinical opportunities and create future commercialization or partnering options if regulatory milestones are achieved.
Bears Say
Persistent UnprofitabilityPersistent operating and net losses show that the business has not reached breakeven and remains financially dependent on future funding or successful development outcomes. Continued losses can constrain investment capacity, weaken earnings quality, and make durable profitability difficult to establish.
Negative Shareholder EquityNegative equity is a major solvency warning because liabilities exceed the recorded asset base and leave limited balance-sheet support for future operations. This fragile capital structure reduces financial flexibility and makes the company more sensitive to additional losses or the need for external capital.
Renewed Cash BurnThe return to sizable operating and free-cash-flow burn indicates that recent cash generation was not sustained. If the pattern continues, AB Science may need additional financing to support research and development, increasing liquidity risk and potentially diluting existing shareholders.
AB Science SA News
ABSCF FAQ
What was AB Science SA’s price range in the past 12 months?
AB Science SA lowest stock price was $1.12 and its highest was $1.45 in the past 12 months.
What is AB Science SA’s market cap?
AB Science SA’s market cap is $63.26M.
When is AB Science SA’s upcoming earnings report date?
AB Science SA’s upcoming earnings report date is Oct 09, 2026 which is in 6 days.
How were AB Science SA’s earnings last quarter?
AB Science SA released its earnings results on May 13, 2026. The company reported -$0.08 earnings per share for the quarter.
Is AB Science SA overvalued?
According to Wall Street analysts AB Science SA’s price is currently Overvalued.
Does AB Science SA pay dividends?
AB Science SA does not currently pay dividends.
What is AB Science SA’s EPS estimate?
AB Science SA’s EPS estimate is -0.08.
How many shares outstanding does AB Science SA have?
AB Science SA has 96,530,785 shares outstanding.
What happened to AB Science SA’s price movement after its last earnings report?
AB Science SA reported an EPS of -$0.08 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of AB Science SA?
Currently, no hedge funds are holding shares in ABSCF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
AB Science SA
AB Science S.A. is a pharmaceutical company dedicated to the discovery, development, and commercialization of protein kinase inhibitors for applications in both human and animal health. Its primary drug candidate, masitinib, a tyrosine kinase inhibitor, is currently undergoing late-stage (Phase III) clinical investigations for a range of serious conditions including prostate cancer, pancreatic cancer, amyotrophic lateral sclerosis (ALS), multiple sclerosis, Alzheimer's disease, severe asthma, and mastocytosis. Additionally, masitinib is being evaluated in Phase II clinical trials for the treatment of Covid-19. The company's pipeline also features AB8939, a synthetic microtubule destabilizer aimed at treating acute myeloid leukemia, and AB20001, which is in Phase 2 trials to assess the safety and efficacy of masitinib combined with isoquercetin in hospitalized patients experiencing moderate to severe COVID-19. Masitinib is sold under the brand name Masivet in the European market. AB Science S.A. was founded in 2001 and is based in Paris, France.